Media coverage about Oncomed Pharmaceuticals (NASDAQ:OMED) has trended somewhat positive on Tuesday, according to Accern Sentiment. The research firm identifies negative and positive news coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores closest to one being the most favorable. Oncomed Pharmaceuticals earned a news impact score of 0.10 on Accern’s scale. Accern also assigned media stories about the biopharmaceutical company an impact score of 46.266569283322 out of 100, indicating that recent news coverage is somewhat unlikely to have an impact on the company’s share price in the near term.
These are some of the news articles that may have effected Accern’s analysis:
A number of research firms recently issued reports on OMED. ValuEngine raised Oncomed Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Wednesday, May 2nd. HC Wainwright reaffirmed a “hold” rating and issued a $3.00 target price on shares of Oncomed Pharmaceuticals in a research report on Friday, March 9th. Finally, Zacks Investment Research downgraded Oncomed Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, May 17th. Six equities research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company presently has an average rating of “Hold” and an average price target of $4.42.
NASDAQ OMED traded down $0.06 during trading on Tuesday, reaching $2.80. 29,133 shares of the company’s stock were exchanged, compared to its average volume of 74,040. The company has a market cap of $109.53 million, a PE ratio of -2.69 and a beta of 1.84. Oncomed Pharmaceuticals has a fifty-two week low of $1.74 and a fifty-two week high of $5.56.
Oncomed Pharmaceuticals (NASDAQ:OMED) last announced its quarterly earnings results on Tuesday, May 8th. The biopharmaceutical company reported ($0.15) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.22) by $0.07. The business had revenue of $7.85 million for the quarter, compared to analyst estimates of $7.27 million. equities analysts forecast that Oncomed Pharmaceuticals will post -0.83 EPS for the current fiscal year.
About Oncomed Pharmaceuticals
OncoMed Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing novel therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence, and metastasis. The company's product candidates and preclinical programs include navicixizumab (anti-DLL4/VEGF Bispecific, OMP-305B83), a monoclonal antibody that targets Delta-like ligand 4 and vascular endothelial growth factor, which has completed a single-agent Phase Ia clinical trial in patients with advanced solid tumors, as well as in two Phase Ib clinical trials for patients with platinum-resistant ovarian cancer and metastatic colorectal cancer; anti-TIGIT (OMP-313M32), a T-cell immunoreceptor with immunoglobulin and ITIM domain, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; GITRL-Fc (OMP-336B11), a glucocorticoid-induced tumor necrosis factor receptor -related protein and its ligand, which is in Phase Ia clinical trial for patients with advanced or metastatic solid tumors; and rosmantuzumab (anti-RSPO3, OMP-131R10), a monoclonal antibody targeting the RSPO-LGR CSC pathway.
Receive News & Ratings for Oncomed Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncomed Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.